Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD)

Patients with chronic kidney disease (CKD) are at high risk of adverse renal and cardiovascular (CV) outcomes, particularly heart failure. We investigated the effects of dapagliflozin inpatients with CKD, with and without type 2 diabetes (T2D). DAPA-CKD is the first trial to test the effects of a SGLT2 inhibitor on renal and CV outcomes in CKD patients without T2D and included patients with a lower eGFR than in prior trials.

Source: Journal of Cardiac Failure - December 1, 2020 Category: Cardiology Authors: John J.v. McMurray, David C. Wheeler, Bergur V. Stefansson, Ricardo Correa-Rotter, Glenn M. Chertow, Tom Greene, Fan Fan Hou, Magnus B. Lindberg, Peter Rossing, C. David Sj öström, Robert D. Toto, Ann Maria Langkilde, Hiddo Jl Heerspink Source Type: research